PriceTargets.com logo

Revvity - PKI Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $131.22
  • Forecasted Upside: ∞
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 05/16/2023 12:59 AM ET
+0 (0.00%)
Get New Revvity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PKI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PKI

Analyst Price Target is $131.22
▲ +∞ Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Revvity in the last 3 months. The average price target is $131.22, with a high forecast of $165.00 and a low forecast of $54.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for PKI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Revvity. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$53.00 ➝ $54.00N/A
11/15/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$52.00 ➝ $54.00N/A
11/2/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$48.00 ➝ $53.00N/A
5/15/2023CitigroupLower Target$170.00 ➝ $160.00Low
5/12/2023Stifel NicolausLower Target$145.00 ➝ $135.00Low
5/12/2023Robert W. BairdLower Target$182.00 ➝ $165.00Low
5/12/2023BarclaysLower Target$140.00 ➝ $125.00Low
2/15/2023Credit Suisse GroupReiterated RatingNeutral$160.00Low
2/15/2023Robert W. BairdLower TargetOutperform$185.00 ➝ $182.00Low
1/24/2023BarclaysLower TargetEqual Weight$145.00 ➝ $140.00Low
12/12/2022CitigroupUpgradeNeutral ➝ Buy$135.00 ➝ $170.00Low
12/6/2022CowenUpgradeMarket Perform ➝ Outperform$164.00Low
12/6/2022CowenUpgradeMarket Perform ➝ Outperform$192.00 ➝ $164.00Low
11/28/2022BarclaysUpgradeUnderweight ➝ Equal Weight$130.00 ➝ $145.00Low
11/14/2022Credit Suisse GroupLower TargetNeutral$175.00 ➝ $160.00Low
11/9/2022Robert W. BairdLower Target$202.00 ➝ $178.00Low
10/6/2022BarclaysLower TargetUnderweight$140.00 ➝ $120.00Low
9/12/2022BarclaysLower TargetUnderweight$149.00 ➝ $140.00Low
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$175.00Low
8/18/2022Stifel NicolausDowngradeBuy ➝ Hold$190.00 ➝ $170.00Low
8/2/2022BarclaysBoost TargetUnderweight$125.00 ➝ $149.00Low
8/2/2022Robert W. BairdBoost TargetOutperform$198.00 ➝ $202.00Low
8/2/2022Bank of AmericaDowngradeBuy ➝ Neutral$178.00Low
7/20/2022UBS GroupInitiated CoverageBuy$160.00Low
7/14/2022The Goldman Sachs GroupLower TargetNeutral$200.00 ➝ $175.00Low
5/17/2022BarclaysInitiated CoverageUnderweight$125.00Medium
5/4/2022Robert W. BairdLower Target$216.00 ➝ $198.00High
5/4/2022CitigroupLower Target$185.00 ➝ $170.00High
12/16/2021The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$200.00High
12/14/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$200.00 ➝ $205.00High
11/17/2021Royal Bank of CanadaBoost TargetOutperform$49.00 ➝ $50.00Medium
11/3/2021Wells Fargo & CompanyBoost TargetOverweight$190.00 ➝ $200.00High
11/3/2021Robert W. BairdBoost TargetHold ➝ Outperform$183.00 ➝ $206.00High
8/9/2021Royal Bank of CanadaBoost TargetOutperform$48.00 ➝ $49.00Medium
7/27/2021Evercore ISIReiterated RatingOutperform$174.00 ➝ $170.86Medium
7/27/2021Robert W. BairdReiterated RatingOutperform$150.00 ➝ $172.11Medium
6/15/2021Wolfe ResearchUpgradeMarket Perform ➝ OutperformLow
2/3/2021CitigroupBoost Target$150.00 ➝ $155.00High
1/7/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$140.00 ➝ $175.00N/A
12/11/2020Smith Barney CitigroupBoost Target$140.00 ➝ $150.00Low
12/2/2020The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
11/12/2020The Goldman Sachs GroupInitiated CoverageBuy$50.00Low
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$150.00Medium
11/9/2020Needham & Company LLCBoost TargetBuy$139.00 ➝ $193.00High
10/29/2020Smith Barney CitigroupBoost Target$120.00 ➝ $140.00Low
10/29/2020Wells Fargo & CompanyBoost TargetEqual Weight$130.00 ➝ $140.00Low
10/29/2020Robert W. BairdBoost TargetOutperform$137.00 ➝ $151.00High
9/11/2020Needham & Company LLCUpgradeHold ➝ Buy$139.00High
8/10/2020BMO Capital MarketsBoost TargetOutperform$44.00 ➝ $45.00Low
7/29/2020JPMorgan Chase & Co.Boost TargetNeutral$85.00 ➝ $105.00High
7/29/2020Stifel NicolausBoost TargetBuy$95.00 ➝ $125.00High
7/29/2020Wells Fargo & CompanyBoost TargetEqual Weight$105.00 ➝ $130.00High
7/29/2020CfraUpgradeHold ➝ BuyHigh
7/13/2020Needham & Company LLCInitiated CoverageHoldHigh
5/7/2020UBS GroupBoost TargetNeutral$95.00 ➝ $96.00Low
5/6/2020Robert W. BairdBoost TargetOutperform$94.00 ➝ $99.00Low
5/6/2020CfraLower TargetHold$100.00 ➝ $94.00Low
5/6/2020JPMorgan Chase & Co.Boost TargetNeutral$80.00 ➝ $85.00Medium
4/28/2020UBS GroupLower TargetNeutral$100.00 ➝ $95.00Low
4/20/2020CitigroupBoost TargetNeutral$70.00 ➝ $85.00Low
4/2/2020JPMorgan Chase & Co.Lower TargetOverweight$49.00 ➝ $45.00High
4/2/2020Stifel NicolausLower TargetBuy$102.00 ➝ $80.00Low
3/30/2020Wells Fargo & CompanyLower TargetEqual Weight$100.00 ➝ $80.00Low
3/26/2020BarclaysLower TargetEqual Weight$100.00 ➝ $94.00Medium
3/20/2020CitigroupLower TargetNeutral$100.00 ➝ $70.00Low
1/28/2020UBS GroupBoost TargetNeutral$92.00 ➝ $100.00High
1/14/2020TD SecuritiesBoost TargetBuy$54.00 ➝ $56.00Medium
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$105.00Low
1/6/2020CitigroupInitiated CoverageNeutral$100.00Medium
1/3/2020Needham & Company LLCInitiated CoverageHold$79.00Medium
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$89.00 ➝ $114.00High
11/21/2019Stifel NicolausReiterated RatingBuyLow
11/14/2019Stifel NicolausInitiated CoverageBuy$102.00High
11/5/2019Raymond JamesReiterated RatingBuy ➝ Average$51.00Low
10/31/2019Needham & Company LLCReiterated RatingHoldHigh
10/31/2019Piper Sandler CompaniesDowngradeOverweight ➝ Neutral$104.00 ➝ $89.00High
10/18/2019UBS GroupLower TargetNeutral$101.00 ➝ $92.00Low
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$105.00Low
7/30/2019UBS GroupBoost TargetNeutral$99.00 ➝ $101.00High
7/19/2019Wood & CompanyReiterated RatingAverage$49.00Medium
7/10/2019Raymond JamesInitiated CoverageOutperformLow
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
5/3/2019Royal Bank of CanadaReiterated RatingHold$41.00Low
4/9/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$115.00High
2/2/2019UBS GroupSet TargetHold$92.00Low
2/1/2019Piper Sandler CompaniesBoost TargetOverweight$104.00Medium
1/16/2019DesjardinsReiterated RatingBuy ➝ Average$45.00Low
1/10/2019CIBCReiterated RatingBuy ➝ Average$44.50Medium
1/6/2019CowenReiterated RatingHold$85.00Low
1/3/2019Morgan StanleyLower TargetOverweight ➝ Overweight$100.00 ➝ $86.00Low
1/2/2019Needham & Company LLCInitiated CoverageHold ➝ Hold$79.00High
(Data available from 11/30/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2023
  • 10 very positive mentions
  • 26 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Revvity logo
Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $127.73
Low: $115.24
High: $137.11

52 Week Range

Now: N/A

Volume

1,633,000 shs

Average Volume

851,117 shs

Market Capitalization

$14.57 billion

P/E Ratio

15.01

Dividend Yield

0.24%

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Revvity?

The following Wall Street analysts have issued stock ratings on Revvity in the last twelve months: Barclays PLC, BMO Capital Markets, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, and TheStreet.
View the latest analyst ratings for PKI.

What is the current price target for Revvity?

9 Wall Street analysts have set twelve-month price targets for Revvity in the last year. Their average twelve-month price target is $131.22. Robert W. Baird has the highest price target set, predicting PKI will reach $165.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $54.00 for Revvity in the next year.
View the latest price targets for PKI.

What is the current consensus analyst rating for Revvity?

Revvity currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PKI.

What other companies compete with Revvity?

Other companies that are similar to Revvity include Waters, Bio-Rad Laboratories, Avantor, Bio-Rad Laboratories and 10x Genomics. Learn More about companies similar to Revvity.

How do I contact Revvity's investor relations team?

Revvity's physical mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company's listed phone number is (781) 663-6900 and its investor relations email address is [email protected]. The official website for Revvity is www.perkinelmer.com. Learn More about contacing Revvity investor relations.